France: ‘New Deal’ To Boost Access To Innovation, Curb Spending & Spur Investment
The French pharmaceutical industry association Leem has welcomed proposals on pricing, funding and access that are expected to feed into negotiations on the social security financing bill for 2024.
You may also be interested in...
This year’s French social security financing bill contains plenty for the pharmaceutical industry to complain about, including price cuts and rebates, although a controversial plan aimed at reducing the prices of older drugs has been put on the back burner.
The head of the European Medicines Agency says a group of international regulators got together to ensure “global alignment” on the approach to be taken on COVID-19 vaccination.
Dissent In Parliament As Commission Claims EU Pharma Revision Will Improve Competitiveness and Access
Proposals on regulatory data protection and transferable exclusivity vouchers to encourage antimicrobial R&D have received mixed reactions from the parliament’s rapporteurs for the draft legislation.